1983 related articles for article (PubMed ID: 25693012)
1. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
2. 3-year invasive disease-free survival with chemotherapy de-escalation using an
Pérez-García JM; Cortés J; Ruiz-Borrego M; Colleoni M; Stradella A; Bermejo B; Dalenc F; Escrivá-de-Romaní S; Calvo Martínez L; Ribelles N; Marmé F; Cortés A; Albacar C; Gebhart G; Prat A; Kerrou K; Schmid P; Braga S; Di Cosimo S; Gion M; Antonarelli G; Popa C; Szostak E; Alcalá-López D; Gener P; Rodríguez-Morató J; Mina L; Sampayo-Cordero M; Llombart-Cussac A;
Lancet; 2024 Apr; 403(10437):1649-1659. PubMed ID: 38582092
[TBL] [Abstract][Full Text] [Related]
3. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S; Harper-Wynne C; Park YH; Franke F; de Laurentiis M; Schumacher-Wulf E; Eiger D; Heeson S; Cardona A; Özyilkan Ö; Morales-Vàsquez F; Metcalfe C; Hafner M; Restuccia E; O'Shaughnessy J
BMC Cancer; 2024 May; 24(1):641. PubMed ID: 38789924
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.
Huang L; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang HC; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Wang H; Lamour F; Song G; Curran M; Duan C; Lysbet de Haas S; Restuccia E; Shao Z
Nat Commun; 2024 Mar; 15(1):2153. PubMed ID: 38461323
[TBL] [Abstract][Full Text] [Related]
5. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Andersson M; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Perez EA
Oncologist; 2017 Oct; 22(10):1160-1168. PubMed ID: 28592618
[TBL] [Abstract][Full Text] [Related]
7. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Siddiqui A; Heeson S; Kiermaier A; Macharia H; Restuccia E; Kang YK
Gastric Cancer; 2023 Jan; 26(1):123-131. PubMed ID: 36066725
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
Ibragimova KIE; Geurts SME; Laczkó D; Meegdes M; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Aaldering KNA; Dercksen MW; Pepels MJAE; Peters NAJB; van de Winkel LMH; van de Wouw AJ; de Fallois A; van Kats MACE; Tjan-Heijnen VCG
Clin Breast Cancer; 2024 Feb; 24(2):103-111. PubMed ID: 38007349
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT
Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347
[TBL] [Abstract][Full Text] [Related]
10. Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
Gu S; Dusza S; Quigley E; Haliasos H; Markova A; Marchetti M; Moy AP; Dang C; Modi S; Lake D; Noor S; Lacouture ME
Breast Cancer Res Treat; 2024 Jan; 203(2):271-280. PubMed ID: 37833451
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
[TBL] [Abstract][Full Text] [Related]
12. HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.
Harbeck N; Beckmann MW; Rody A; Schneeweiss A; Müller V; Fehm T; Marschner N; Gluz O; Schrader I; Heinrich G; Untch M; Jackisch C
Breast Care (Basel); 2013 Mar; 8(1):49-55. PubMed ID: 24715843
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Extra JM; Antoine EC; Vincent-Salomon A; Delozier T; Kerbrat P; Bethune-Volters A; Guastalla JP; Spielmann M; Mauriac L; Misset JL; Serin D; Campone M; Hebert C; Remblier C; Bergougnoux L; Campana F; Namer M
Oncologist; 2010; 15(8):799-809. PubMed ID: 20671105
[TBL] [Abstract][Full Text] [Related]
14. Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Geurts SME; Ibragimova KIE; Ding N; Meegdes M; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Dercksen MW; Aaldering KNA; Pepels MJAE; van de Winkel L; Peters NAJB; van de Wouw AJ; Maaskant SAJG; Teeuwen-Dedroog NJA; van Nijnatten TJA; de Boer M; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jun; 205(2):287-302. PubMed ID: 38381274
[TBL] [Abstract][Full Text] [Related]
15. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gianni L; Lladó A; Bianchi G; Cortes J; Kellokumpu-Lehtinen PL; Cameron DA; Miles D; Salvagni S; Wardley A; Goeminne JC; Hersberger V; Baselga J
J Clin Oncol; 2010 Mar; 28(7):1131-7. PubMed ID: 20124183
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan.
Osako T; Nishimura R; Nishiyama Y; Fujisue M
Mol Clin Oncol; 2015 Nov; 3(6):1268-1274. PubMed ID: 26807231
[TBL] [Abstract][Full Text] [Related]
17. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.
Cancello G; Montagna E; D'Agostino D; Giuliano M; Giordano A; Di Lorenzo G; Plaitano M; De Placido S; De Laurentiis M
Breast Cancer Res; 2008; 10(4):R60. PubMed ID: 18631394
[TBL] [Abstract][Full Text] [Related]
18. Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Blas PE; Rodriguez ESR; Williams HL; Levin MK; Bell JSK; Pierobon M; Barrett AS; Petricoin EF; O'Shaughnessy JA
Cancer Rep (Hoboken); 2024 Mar; 7(3):e1954. PubMed ID: 38441358
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Debien V; Agostinetto E; Bruzzone M; Ceppi M; Martins-Branco D; Molinelli C; Jacobs F; Nader-Marta G; Lambertini M; de Azambuja E
Clin Breast Cancer; 2024 Feb; ():. PubMed ID: 38514306
[TBL] [Abstract][Full Text] [Related]
20. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?
Sun R; Wei LJ
JAMA Oncol; 2024 Apr; 10(4):537. PubMed ID: 38329744
[No Abstract] [Full Text] [Related]
[Next] [New Search]
